Best of FSR Annual Meeting 2020: Immunology Bootcamp – Advances in Targeted Therapies

1.25 CME
1.25 ABIM MOC
75 MINS
$0 FEE
SAVE
Best of FSR Annual Meeting 2020: Immunology Bootcamp – Advances in Targeted Therapies

Overview

Provider Statement

This continuing medical education activity is provided by Vindico Medical Education


Support Statement

This activity is supported by educational grants from AbbVie Inc.; Amgen; Bristol-Myers Squibb; and Sanofi Genzyme.


Activity Description

The hallmarks of immune-mediated inflammatory diseases (IMIDs) result from the intricate interplay of cells, cytokines, and other components of the immune system. Similar pathology underlies related rheumatic diseases, such as rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, systemic lupus erythematosus, and giant cell arteritis. Understanding the immunopathology of these diseases is essential to understanding the mechanisms of action through which different medications exert their effects. Another emerging trend in rheumatology is the identification and management of immune-related adverse events associated with new cancer immunotherapies; however, providers lack experience in managing these conditions. Biosimilars are another possible new treatment option in IMIDs. In this educational activity, Dr. Vibeke Strand discusses the latest on the pathogenesis and treatments of IMIDs.


Target Audience

The intended audience for this activity is rheumatologists and other health care professionals involved in the management of patients with immune-mediated inflammatory diseases.


Learning Objectives

Upon successful completion of this educational activity, participants should be better able to:

  • Examine common signaling pathways that underlie chronic immune-mediated inflammatory conditions as well as the molecular targets of available and emerging immune-based therapies.
  • Select treatment for patients with IMID based on the latest clinical evidence and patient characteristics.
  • Communicate with patients regarding biosimilars to identify patients who may prefer a biosimilar over a reference biologic.

Activity Chair

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH


Faculty

Adam Brown, MD
Center for Vasculitis Care and Research
Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH

Cassandra Calabrese, DO
Rheumatology and Infectious Disease
Cleveland Clinic Foundation
Cleveland, OH

Vibeke Strand, MD, MACR, FACP
Biopharmaceutical Consultant
Adjunct Clinical Professor
Division of Immunology/Rheumatology
Stanford University School of Medicine
Palo Alto, CA


Reviewers

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP 
Ronald A. Codario, Jr., MD


Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Successful completion of this CME activity enables the participant to earn up to 1.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

This enduring material is approved for 1 year from the date of original release, October 29, 2020 to October 28, 2021.


How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.


Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears below.  

Activity Chair and Faculty report the following relationship(s)

Adam Brown, MD
Honoraria: Healio

Cassandra Calabrese, DO
Consulting Fee: AbbVie
Speakers Bureau: Regeneron

Leonard H. Calabrese, DO
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Kiniksa, Lilly, Pfizer, Sanofi-Regeneron, UCB
Speakers Bureau: AbbVie, Bristol-Myers Squibb, Crescendo, Genentech, Horizon, Sanofi, UCB

Vibeke Strand, MD, MACR, FACP
Consulting Fee: AbbVie, Amgen, Arena, Asana, AstraZeneca, Bayer, Bioventus, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Corrona, Crescendo/Myriad Genetics, EMD Serono, Eupraxia, Flexion, Galapagos, Genentech/Roche, Gilead, GlaxoSmithKline, Glenmark, Horizon, Inmedix, Janssen, Kezar, Kypha, Lilly, Merck, Novartis, Pfizer, Regeneron, Royalty, RRD, Samsung, Samumed, Sandoz, Sanofi, Selecta, Servier, SetPoint Medical, SKK, UCB

Reviewers report the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose. 

Ronald A. Codario, Jr., MD
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.


Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non—FDA-approved or investigational use of products/devices.


Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.


CME Questions?

Contact us at cme@vindicoCME.com